Northern Trust Corp Oncorus, Inc. Transaction History

Northern Trust Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.28 - $0.45 $121 - $195	-435 Reduced 1.5%	28,525 $9,000
Q2 2022 Aug 12, 2022	SELL	$1.04 - $1.86 $137,042 - $245,095	-131,772 Reduced 81.98%	28,960 $37,000
Q1 2022 May 13, 2022	SELL	$1.44 - $5.62 $15,901 - $62,061	-11,043 Reduced 6.43%	160,732 $286,000
Q4 2021 Feb 08, 2022	BUY	$5.03 - $11.63 $15,064 - $34,831	2,995 Added 1.77%	171,775 $906,000
Q3 2021 Nov 15, 2021	BUY	$9.29 - $14.27 $2,573 - $3,952	277 Added 0.16%	168,780 $1.58 Million
Q2 2021 Aug 13, 2021	BUY	$13.3 - $17.3 $1.1 Million - $1.43 Million	82,843 Added 96.71%	168,503 $2.33 Million
Q1 2021 May 12, 2021	BUY	$11.89 - $35.55 $117,485 - $351,269	9,881 Added 13.04%	85,660 $1.19 Million
Q4 2020 Feb 11, 2021	BUY	$15.0 - $35.15 $1.14 Million - $2.66 Million	75,779 New	75,779 $2.45 Million

Ticker ONCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,973,100
Description
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.